2-([pyridin-4-ylmethyl]amino)benzoic acid | 267891-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-([pyridin-4-ylmethyl]amino)benzoic acid
• 英文别名: 2-(4-pyridylmethyl)aminobenzoic acid；2-(Pyridin-4-ylmethylamino)benzoic acid
• CAS: 267891-86-1
• 化学式: C₁₃H₁₂N₂O₂
• mdl: MFCD03019340
• 分子量: 228.25
• InChiKey: UPPNJZSFIIFBPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-([pyridin-4-ylmethyl]amino)benzoic acid 在 copper(l) iodide 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 2-(pyridine-4-yl)-4H-benzo[d][1,3]oxazine-4-one
  参考文献：
  名称：

  Copper catalyzed CN bond formation/C–H activation: synthesis of aryl 4H-3,1-benzoxazin-4-ones

  摘要：

  We have developed a practical and efficient synthesis of 2-phenyl-4H-benzo[d][1,3]oxazine-4-one derivatives through copper catalyzed tandem reaction of 2-iodobenzoic acid with arylmethanamines under aerobic conditions. Compared to the literature methods toward the synthesis of 2-phenyl-4H-benzo[d][1,3]oxazine-4-one, the synthetic method reported in this Letter has broad substrate scope, mild reaction condition, and uses an inexpensive catalyst. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.11.070
• 作为产物：
  描述：

  methyl 2-((pyridin-4-ylmethyl)amino)benzoate 在 sodium hydroxide 作用下， 反应 3.0h， 以98.1%的产率得到2-([pyridin-4-ylmethyl]amino)benzoic acid
  参考文献：
  名称：

  Synthesis and evaluation of novel radioiodinated anthranilate derivatives for in vivo imaging of vascular endothelial growth factor receptor with single-photon emission computed tomography

  摘要：

  angiogenesis 促进肿瘤存活并促进恶性肿瘤的发展。血管内皮生长因子 (VEGF)/VEGF 受体 (VEGFR) 酪氨酸激酶 (TK) 信号通路是介导血管生成的关键因素，这表明该通路可能是诊断和治疗的目标。在本研究中，我们旨在开发适用于体内 VEGFR 成像的小分子放射碘化探针，考虑到单光子发射计算机断层扫描 (SPECT) 的多功能性和实用性。我们基于针对 VEGFR-TK 的抗癌药物结构设计并合成了四种放射碘化的氨基苯甲酸化合物 (6a–d)。通过细胞增殖抑制测定和中性溶液中孵育后的放射薄层色谱评估了相应冷化合物 4a–d 的抑制效力和化合物 6a–d 的体外稳定性。通过在肿瘤小鼠中静脉注射测试化合物后测定感兴趣组织的放射性来评估体内生物分布。在肿瘤小鼠中使用选择性 VEGFR-TK 抑制剂进行的体外和体内封闭实验，以及 SPECT/计算机断层扫描 (CT) 成像。放射碘化化合物 6a–d 的放射化学产率超过 68.0%，放射化学纯度超过 95%。由于化合物 4a–d 显示出较强的抑制效力，而化合物 6c 和 6d 显示出较高的体外稳定性，因此对 6c ([125I]m-NPAM) 和 6d ([125I]p-NPAM) 进行了进一步评估。体内生物分布分析显示，[125I]p-NPAM 给药后肿瘤与血液的放射活性比在 24 小时后超过 4。给予 [125I]p-NPAM 后，培养的肿瘤细胞和肿瘤异种移植体中放射活性的累积显著被抑制剂预处理所阻断。与抑制剂预处理的肿瘤小鼠相比，使用 SPECT/CT 在 [125I]p-NPAM 注射后 24 小时清晰显示肿瘤。 [125I]p-NPAM 可能作为未来开发临床可用 VEGFR 成像探针的先导化合物具有潜在的应用价值。

  DOI：

  10.1007/s12149-020-01475-6

文献信息

• N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20020019414A1

  公开（公告）日：2002-02-14

  1 Described are compounds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 -(CH 2 )n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 1 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y═SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  描述的是化合物的结构式（I），其中W是O或S；X是NR8；Y是CR9R10-(CH2)n，其中R9和R10彼此独立地是氢或较低的烷基，n是从0到3的整数；或Y是SO2；R1是芳基；R2是一个含有一个或多个环氮原子的单环或双环杂环基团，但R2不能代表2-邻苯二甲酰胺，并且在Y为SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任何一个，独立于其他，是H或除氢之外的取代基；R7和R8，彼此独立地是H或较低的烷基；或其N-氧化物或药用可接受的盐，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制产生反应的恶性疾病的药物产品。结构式（I）的化合物可用于治疗恶性疾病，如肿瘤疾病，视网膜病和老年性黄斑变性等。
• Ortho-substituted anthranilic acid amides and their use as medicaments
  申请人：——

  公开号：US20040102441A1

  公开（公告）日：2004-05-27

  Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.

  本文描述了邻位取代的蒽酸酰胺及其用途，作为治疗由持续性血管生成引发的疾病的药物。
• [EN] N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE N-ARYL(THIO)ANTHRANILIQUE ACIDE AMIDE, LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DU RECEPTEUR VEGF
  申请人：NOVARTIS AG

  公开号：WO2000027820A1

  公开（公告）日：2000-05-18

  Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10-(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  本文描述了式(I)的化合物，其中W是O或S；X是NR8；Y是CR9R10-(CH2)n，其中R9和R10独立地是氢或低级烷基，n是0至3的整数；或者Y是SO2；R1是芳基；R2是一个含有一个或多个环氮原子的单环或双环杂环基团，但R2不能代表2-苯甲酰亚胺基，且在Y = SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任何一个，除了氢之外，都是取代基；R7和R8独立地是氢或低级烷基；或其N-氧化物或药学上可接受的盐，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的制药产品。式(I)的化合物可用于治疗肿瘤疾病、视网膜病变和年龄相关性黄斑变性等疾病。
• N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20040198782A1

  公开（公告）日：2004-10-07

  1 Described are compunds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 —(CH 2 ) n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 2 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y=SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  描述了化合物的公式(I)，其中W为O或S; X为NR8; Y为CR9R10—(CH2)n，其中R9和R10独立地为氢或低烷基，n为0至3的整数，包括0和3; 或Y为SO2; R2为芳基; R2为一种单环或双环杂环芳基，包括一个或多个环氮原子，但R2不能表示2-邻苯二甲酰亚胺基，且在Y = SO2的情况下不能表示2,1,3-苯并噻二唑-4-基; R3、R4、R5和R6中的任何一个，除了氢之外，都是取代基; R7和R8独立地为氢或低烷基; 或其N-氧化物或药学上可接受的盐，用于制备治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的制药产品。公式(I)的化合物可用于治疗肿瘤疾病，如肿瘤疾病，视网膜病和年龄相关性黄斑变性等。
• N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20030064992A1

  公开（公告）日：2003-04-03

  1 Described are compunds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 —(CH 2 )n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 1 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y=SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  本文描述了式(I)的化合物，其中W为O或S；X为NR8；Y为CR9R10—(CH2)n，其中R9和R10独立地为氢或低碳基，n为0至3的整数，或Y为SO2；R1为芳基；R2为一个单环或双环杂芳基，其中包含一个或多个环氮原子，但R2不能代表2-苯酰亚胺基，且在Y=SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任意一个，独立于其他的，为H或除氢以外的取代基；且R7和R8独立地为H或低碳基；或其N-氧化物或药学上可接受的盐，用于制备治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的药物产品。式(I)的化合物可用于治疗肿瘤疾病，如肿瘤疾病、视网膜病变和老年性黄斑变性等。